Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

NCT06728865 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)
EGFR Mutation-Positive Lung Cancer
Brain Metastases
Leptomeningeal Metastases
Intracranial Tumor Progression

Interventions

DRUG: The treatment regimen is Furmonertinib combined with Bevacizumab.

Sponsor

Li-kun Chen